Disaster Preparedness of Older People (SIMAH)

February 3, 2025 updated by: Sebahat Gozum, Akdeniz University

The Effect of the Disaster Preparedness Education Program Based on the Health Belief Model on the Disaster Preparedness of Older People in the Community: Cluster Randomized Controlled Trial

Disasters; It is an important public health problem of uncertain time, causing loss of life and property, having severe economic consequences, and causing serious health problems in the long term. In dealing with disasters, it is expected that measures to reduce the damage and losses caused by the hazards that the disaster may cause are taken during the disaster preparedness phase. For this reason, the individuals in the society should be educated before the disaster and their preparedness for the disaster should be ensured. While it is possible for young age groups to access information, participate in public education and self-learning, they need support for their preparedness for disasters because there is no disaster education program specific to older individuals. This project was designed as a single-blind (participant) randomized controlled study in order to examine the effect of the Disaster Preparedness Education Program (SIMAH) based on the Health Belief Model of older people in the society on their preparedness to disasters according to the active control group to which the public education materials prepared by the Disaster and Emergency Management Presidency (AFAD) will be given. The research was planned to be carried out in a total of six clusters in Antalya province Muratpaşa district and Konyaaltı district between October and December 2023 in older people houses, retirement cafes and district parks where older people are concentrated. The sample size was calculated as 66 older individuals (intervention: 33, control: 33). The SIMAH Program, which includes interactive group training for three months, public education materials prepared by AFAD, and reminder phone messages, will be applied to the initiative group. Public education materials prepared by AFAD will be given to the active control group in the same period. Outcomes will be measured with the Disaster Readiness Scale, the General Disaster Preparedness Belief Scale, and the Individual Disaster Preparedness Evaluation Form, before the intervention, after the training program, and three months later.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
66

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Turkey
      • Antalya, Turkey, 07058
        • Active Life Center, Retirement Coffees

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Those who come to the places where the research will be carried out,
  • Those aged 60 and over,
  • Those who can speak and understand Turkish,
  • Those who get 9 points or more from the Mini-Mental State Examination,
  • Those who have and can use a smart phone,
  • Those who have voluntarily agreed to participate in the study,
  • One elderly person from the same household will be included in this study.

Exclusion Criteria:

-Those who have previously received disaster preparedness training will not be included in the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Disaster Preparedness Education Program (SIMAH)
Behavioral: Disaster Preparedness Education Program
The SIMAH Program includes interactive group training for three months, public education materials prepared by AFAD, and reminder phone messages will apply.
Other Names:
  • SIMAH
Active Comparator: Disaster and Emergency Management Presidency (AFAD) Education Program
Other: Disaster and Emergency Management Presidency Education
Public education materials prepared by the Disaster and Emergency Management Presidency (AFAD) will give.
Other Names:
  • AFAD

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Disaster Readiness Scale
Time Frame: Change in Disaster Readiness Level at second week and third months from baseline
The minimum score that can be obtained from the scale is 13, and the maximum score is 52. As the score obtained from the scale increases, the level of disaster preparedness increases.
Change in Disaster Readiness Level at second week and third months from baseline
General Disaster Preparedness Belief Scale
Time Frame: Change in Disaster Preparedness Beliefs Level at second week and third months from baseline
A minimum of 31 points and a maximum of 155 points are taken from the scale. As the score obtained from the scale increases, the level of disaster preparedness belief increases.
Change in Disaster Preparedness Beliefs Level at second week and third months from baseline
Individual Disaster Preparedness Evaluation Form
Time Frame: Change in Individual Disaster Preparedness Level at third months from baseline
The Individual Disaster Preparedness Evaluation Form consists of 31 items. This form has been prepared to evaluate individual disaster preparations, such as whether the mobile applications that the participants can use in case of disaster are installed on their phones, whether the disaster and emergency kit is prepared, whether arrangements are made in the home environment to prevent injuries during disasters, and whether disaster insurances are made to reduce the effects of disasters. As the score obtained from the form increases, the individual preparedness for the disaster increases.
Change in Individual Disaster Preparedness Level at third months from baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Akdeniz University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
October 1, 2023

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
February 3, 2025

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
February 3, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
April 26, 2023

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 5, 2023

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
May 16, 2023

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 25, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 3, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
May 1, 2023

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 007

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings